Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 28, 2026Molecular CancerOpen Access

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLuis Luna-RamírezRGRosula Garcia-NavasESEugenio Santos

Discussion

Loading...

Member takes

Overview

This review evaluates SOS1 as a therapeutic target in RAS-dependent cancers, suggesting promising implications for treatment.

Key Points

  • The review aims to summarize the role of SOS1 as a therapeutic target in RAS-dependent cancers and explore its potential benefits and challenges.
  • Comprehensive evaluation of small-molecule SOS1 inhibitory drugs and SOS1 degraders.
  • Analysis of preclinical, in vitro, and in vivo model responses across tumor types.
  • Discussion of SOS1 inhibitors combined with RAS/MAPK pathway antagonists.
  • Overview of ongoing clinical trials on SOS1 inhibitors.
  • SOS1 is identified as a crucial therapeutic target due to its role in RAS-driven malignancies.
  • Inhibitors showcase specific therapeutic responses in various experimental models.
  • Combination therapies with SOS1 inhibitors exhibit promising synergistic effects.
  • SOS1 inhibition may help overcome resistance to FDA-approved RAS inhibitors.

Cite This Study

Luna-Ramírez et al. (2026) studied this question.

synapsesocial.com/papers/69c770888bbfbc51511e09cdhttps://doi.org/10.1186/s12943-026-02632-7
View Full Paper
Ask AI
Bookmark
Share